Policy

A US appeals court has blocked Novartis from selling the first biosimilar to be approved in the United States.

Will Sandoz' biosimilar, first ever in the US, ever see the light of day?

A discussion on meaningful measurement and driving greater value in healthcare, and the role of the National Quality Forum.

Karen Ignagni is stepping down as president and chief executive officer of America's Health Insurance Plans for a position with EmblemHealth in New York.

Use of specialist visits decreased by patients whose primary care physicians transformed their practices into patient-centered medical homes, 1 year after medical home implementation.

The authors examine 4 alternative payment models for oncology care that shift away from fee-for-service and move progressively toward greater bundling, either across providers or across payments.

The use of an 80% threshold or other binary cut point may be insufficient for characterizing the relationship between medication adherence and Medicare spending.

Venous thromboembolism during or after recent hospitalization for medical illness contributes a substantial economic burden to society across all hospital and ambulatory care delivered.

While the marketing of the first biosimilar to be approved in the US market, Zarxio, has been delayed due to a court order, the FDA is providing guidance to manufacturers to help them effectively navigate the process of product development.

The appeals court decision has ensured that Novartis cannot bring its biosimilar Zarxio (filgrastim), which provides immune support to cancer patients, to the market at least till June 3.

Pharmacy and therapeutic committees view potential cost savings as the most important factor when recommending formulary placement, according to a new survey.

While lawmakers, payers, and patient advocates are raising a voice against the sky-rocketing costs of the newer breakthorugh agents in cancer, the drug developers can boast a strong start to the year with big sales figures.